Cytokinetics, Incorporated (CYTK) Financial Ratios
24 years of historical data (2002–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low5.1·High24.6
P/FCF
N/A
—
5yr avg: N/A
30Y Low14.6·High94.0
P/B Ratio
N/A
—
5yr avg: 14.37
30Y Low1.0·High14.4
ROE
↓
N/A
—
5yr avg: -346.3%
30Y Low-479%·High32%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.0·High1.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CYTK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cytokinetics, Incorporated currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9.2B | $7.6B | $5.3B | $8.1B | $4.1B | $3.5B | $1.3B | $611M | $344M | $403M | $517M |
| Enterprise Value | $9.6B | $8.0B | $6.0B | $8.7B | $4.8B | $3.7B | $1.4B | $711M | $344M | $309M | $478M |
| P/E Ratio → | -11.44 | — | — | — | — | — | — | — | — | — | 31.15 |
| P/S Ratio | 104.70 | 86.68 | 285.13 | 1070.22 | 43.51 | 49.76 | 24.02 | 22.74 | 10.92 | 30.12 | 4.86 |
| P/B Ratio | — | — | — | — | — | 14.37 | 11.83 | — | 13.26 | 3.67 | 5.48 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 14.61 |
| P/OCF | — | — | — | — | — | — | 149.93 | — | — | — | 13.98 |
P/E links to full P/E history page with 30-year chart
CYTK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 91.25 | 322.69 | 1155.58 | 50.75 | 51.99 | 25.02 | 26.44 | 10.92 | 23.13 | 4.49 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | 24.58 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | 33.67 |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 13.50 |
CYTK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cytokinetics, Incorporated earns an operating margin of -695.4%. Operating margins have expanded from -6589.7% to -695.4% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 88.5% | -1737.2% | -4284.1% | -154.6% | -127.1% | -73.7% | -220.5% | -183.0% | -575.5% | 39.5% |
| Operating Margin | -695.4% | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% |
| Net Profit Margin | -891.6% | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -572.1% | -120.5% | -248.5% | -1622.9% | -156.6% | -125.2% | 20.2% |
| ROA | -55.5% | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% |
| ROIC | -305.3% | -305.3% | -98.7% | -89.3% | -49.7% | -49.0% | -54.6% | -129.2% | -313.8% | -238.6% | 38.4% |
| ROCE | -50.1% | -50.1% | -55.2% | -60.1% | -38.1% | -29.3% | -24.5% | -43.7% | -39.4% | -56.8% | 17.0% |
CYTK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $402M ($1.3B total debt minus $882M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 1.11 | 1.23 | — | 1.64 | 0.29 | 0.29 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 1.41 |
| Net Debt / Equity | — | — | — | — | — | 0.64 | 0.49 | — | 0.01 | -0.85 | -0.42 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | -2.03 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -1.12 |
| Interest Coverage | -7.56 | -7.56 | -5.81 | -8.13 | -6.60 | -6.34 | -2.29 | -3.45 | -3.93 | -6.52 | 6.35 |
CYTK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cytokinetics, Incorporated's current ratio of 4.53x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.12x to 4.53x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.53 | 4.53 | 6.17 | 6.12 | 9.40 | 7.45 | 15.20 | 8.98 | 9.36 | 8.45 | 4.77 |
| Quick Ratio | 4.53 | 4.53 | 6.17 | 6.12 | 9.40 | 7.45 | 15.20 | 8.98 | 9.66 | 8.45 | 4.77 |
| Cash Ratio | 4.36 | 4.36 | 5.99 | 5.99 | 9.25 | 6.56 | 14.87 | 8.65 | 8.95 | 8.29 | 4.70 |
| Asset Turnover | — | 0.06 | 0.01 | 0.01 | 0.09 | 0.08 | 0.10 | 0.09 | 0.15 | 0.05 | 0.63 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 328.96 | 62.19 | 0.57 | 268.56 | 28.90 | 70.14 | 78.62 | 30.36 | 0.08 |
CYTK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cytokinetics, Incorporated does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | 3.2% |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 6.8% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $120M | $112M | $97M | $90M | $77M | $65M | $58M | $54M | $49M | $43M |
Peer Comparison
Compare CYTK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CYTKYou | $9B | -11.4 | — | — | 88.5% | -695.4% | — | -305.3% | — |
 MDGL | $12B | -42.0 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 KRYS | $9B | 42.2 | 47.8 | 45.1 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 TENX | $71M | -10.5 | — | — | — | — | -35.2% | — | — |
 ATHA | $17M | -0.2 | — | — | — | — | -290.8% | — | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 ARWR | $11B | -6486.9 | 91.8 | 70.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 24 years · Updated daily
See CYTK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CYTK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CYTK vs MDGL
Side-by-side business, growth, and profitability comparison vs Madrigal Pharmaceuticals, Inc..
Start ComparisonCYTK — Frequently Asked Questions
Quick answers to the most common questions about buying CYTK stock.
What is Cytokinetics, Incorporated's P/E ratio?
Cytokinetics, Incorporated's current P/E ratio is -11.4x. The historical average is 19.0x.
Is CYTK stock overvalued?
Based on historical data, Cytokinetics, Incorporated is trading at a P/E of -11.4x. Compare with industry peers and growth rates for a complete picture.
What are Cytokinetics, Incorporated's profit margins?
Cytokinetics, Incorporated has 88.5% gross margin and -695.4% operating margin.